Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.73 |
| ▸ | HTR7 | P34969 | 5/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 3/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9811592 | 0.98 | HTR1A (0.71) | HTR1AHTR7KCNH2DRD2SIGMAR1 | |
| SCHEMBL8045431 | 0.90 | KCNH2 (0.69) | HTR1AHTR7KCNH2DRD2SIGMAR1 | |
| SCHEMBL13234969 | 0.88 | HTR1A (0.58) | HTR1AHTR7DRD2SIGMAR1MAPT | |
| SCHEMBL5848982 | 0.87 | KCNH2 (0.75) | HTR1AHTR7KCNH2DRD2SIGMAR1 | |
| SCHEMBL3870090 | 0.86 | HTR1A (0.69) | HTR1AHTR7KCNH2DRD2SIGMAR1 | |
| SCHEMBL13589528 | 0.86 | HTR1A (0.69) | HTR1AHTR7KCNH2DRD2SIGMAR1 | |
| SCHEMBL13234959 | 0.86 | LMNA (0.57) | HTR1AHTR7DRD2TSHRLMNA | |
| SCHEMBL13234974 | 0.86 | HTR1A (0.61) | HTR1AHTR7DRD2SIGMAR1LMNA | |
| SCHEMBL2881711 | 0.86 | HTR1A (0.57) | HTR1AHTR7DRD2SIGMAR1MAPT | |
| SCHEMBL2881745 | 0.85 | HTR1A (0.60) | HTR1AHTR7DRD2SIGMAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118265692-B | Carbon nucleus cationic lipid | 厦门赛诺邦格生物科技股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2024198497-A1 | AMINO LIPID, AND LIPID NANOPARTICLES AND USE THEREOF | 深圳虹信生物科技有限公司 | 2024-10-03 | — | — | WO | disclosed |
| CN-118724740-A | Amino lipids, lipid nanoparticles and uses thereof | 深圳虹信生物科技有限公司 | 2024-10-01 | — | — | CN | disclosed |
| EP-2388003-B1 | Colchicine derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3207929-B1 | COLCHICINE DERIVATIVES FOR THE TREATMENT OF CANCER | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3207929-A2 | COLCHICINE DERIVATIVES | California Pacific Medical Center (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-1617843-B1 | COLCHICINE DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-1643987-B1 | PODOPHYLLOTOXIN DERIVATIVES | CALIFORNIA PACIFIC MED CENTER (US) | 2016-11-30 | — | — | EP | disclosed |
| US-8158809-B2 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2388003-A2 | Colchicine derivatives | California Pacific Medical Center (US) | 2011-11-23 | — | — | EP | disclosed |
| CN-1511159-A | Nitrogen-based camptothecin derivatives | ����������̫ƽ��ҽѧ���� | 2004-07-07 | — | — | CN | disclosed |
| US-20040063740-A1 | For treatment of cancer | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2004-04-01 | — | — | US | disclosed |
| EP-1383772-A2 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | California Pacific Medical Center (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003101998-A1 | NITROGEN-BASED HOMO-CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-04-17 | — | — | US | disclosed |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-02-13 | — | — | US | disclosed |
| WO-2002070525-A2 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2002-09-12 | — | — | WO | disclosed |
| US-6403604-B1 | ANTITUMOR | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-06-11 | — | — | US | disclosed |
| US-5486517-A | Benzimidazoles and imidazopyridines as central nervous system agents | WARNER-LAMBERT COMPANY (US) | 1996-01-23 | — | — | US | disclosed |
| WO-1995030659-A1 | BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINERGIC AGENTS, ESP. SELECTIVE FOR THE DOPAMINE D3 RECEPTOR | WARNER-LAMBERT COMPANY (US) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063740-A1 | For treatment of cancer | MGMT, PAICS, DCK | HTR1A 1728/4885HTR7 541/4885KCNH2 2795/4885 |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | HTR1A 2437/4885HTR7 1517/4885KCNH2 3499/4885 |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | HTR1A 2437/4885HTR7 1517/4885KCNH2 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.